Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Delcath Systems received a “Moderate Buy” consensus from seven analysts: five rated it a buy, one a strong buy, and one a sell. The average 12-month price target is $23.17, above the stock’s $16.25 opening price.
• Recent analysts raised their targets, including HC Wainwright to $32 and BTIG Research to $21, while Zacks upgraded the stock to “strong buy.”
• Delcath exceeded quarterly expectations, reporting $0.07 EPS versus a $0.09 loss estimate and revenue of $29.13 million against a $26.25 million consensus forecast; institutional investors own 61.12% of the company.

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $23.1667.

Several equities analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. BTIG Research increased their price objective on Delcath Systems from $17.00 to $21.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Delcath Systems from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, September 4th. Zacks Research raised shares of Delcath Systems from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 10th. Finally, Wall Street Zen upgraded shares of Delcath Systems from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th.

Delcath Systems Trading Up 0.2%

Shares of DCTH opened at $16.25 on Friday. The stock has a market capitalization of $563.86 million, a price-to-earnings ratio of 1,626.63 and a beta of 0.57. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $17.42. The firm has a fifty day simple moving average of $14.99 and a 200 day simple moving average of $12.26.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.16. The business had revenue of $29.13 million for the quarter, compared to the consensus estimate of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. As a group, research analysts predict that Delcath Systems will post -0.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC acquired a new stake in Delcath Systems in the second quarter valued at $48,000. IFP Advisors Inc acquired a new position in Delcath Systems during the 2nd quarter worth about $52,000. Royal Bank of Canada grew its position in shares of Delcath Systems by 14.8% in the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company's stock valued at $170,000 after buying an additional 2,364 shares during the last quarter. Leonteq Securities AG acquired a new stake in shares of Delcath Systems in the fourth quarter valued at about $293,000. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Delcath Systems during the first quarter worth about $306,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc NASDAQ: DCTH is an oncology company focused on developing and commercializing liver-directed therapies for patients with primary and metastatic cancers of the liver. Its technology is designed to deliver high concentrations of chemotherapy to the liver while limiting systemic exposure.

The company's primary product is the HEPZATO KIT, a combination of melphalan hydrochloride and the Hepatic Delivery System. The treatment is used to perform percutaneous hepatic perfusion, a procedure in which the liver is temporarily isolated so chemotherapy can be administered directly to it and then filtered before the blood returns to the patient's circulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.